Chris Polman, Free University of Amsterdam Abstract N Engl J Med 2006;345:899 Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis &#
Chris Polman, Free University of AmsterdamAbstract N Engl J Med 2006;345:899Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis – might increased the risk of a fatal viral infection, two-year randomised study finding have now given some reassurance that patients with relapsing disease can be treated.
Related Episodes
Tropical Health Research: London Scientist Honored
Brian Greenwood Brian Greenwood, London School of Hygiene and Tropical Medicine Brian Greenwood has won the Hideyo Noguchi Africa Prize for his numerous achievements in tropical disease research. He t
Audio Journal of Oncology in Advance – March 15th, 2008
Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007
Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon
Kenneth Anderson Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston Multiple myeloma may soon be consi